Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For ... The deal will be funded by existing cash and new committed bank debt facilities. Net debt is expected to be approximately ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on ...

Sanofi said this morning that its pipeline includes ... build-up to an R&D presentation to investors that will be held in New York later today, and also after the France-headquartered group ...

NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...

Sanofi named a new chief scientific officer this week, part of a series of moves that the drug company has argued will establish it as being more focused on research and development than in the past.

Sanofi's new medicine, intending to benefit patients with certain forms of multiple sclerosis. Tolebrutinib recently had three Phase 3 readouts and we are pleased already being able to present ...

French healthcare company Sanofi has decided to halt work on its once praised breast cancer medication amcenestrant after a second failed clinical trial. A possible new coronavirus vaccine ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent, costly ...